Antibacterial properties and carbonic anhydrase inhibition profiles of azido sulfonyl carbamate derivatives

Creative Commons License

Güller P., Atmaca U., Güller U., Çalışır U., Dursun F.

Future Medicinal Chemistry, cilt.13, sa.15, ss.1285-1299, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 15
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4155/fmc-2020-0387
  • Dergi Adı: Future Medicinal Chemistry
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1285-1299
  • Anahtar Kelimeler: antibacterial, azido sulfonyl carbamate, carbonic anhydrase, drug likeness, structure-activity relationship, THERAPEUTIC APPLICATIONS, ANTIMICROBIAL ACTIVITY, DRUGS, ANTICANCER, DISCOVERY, IX
  • Atatürk Üniversitesi Adresli: Evet

Özet

The aim of this study was to identify inhibition of carbonic anhydrase I and II (CA I and II) isozymes
by azido sulfonyl carbamates through both in vitro and in silico approaches and also to determine the
drug-likeness properties and antibacterial activities of azido sulfonyl carbamates. Methods & Results: In
vitro inhibition and molecular docking studies of azido sulfonyl carbamate derivatives (1–4) on isozymes
were performed. Except for derivative 4, all derivatives inhibited human CA I and II. Almost all compounds
had antibacterial effects. The docking results showed that compound 3 had the best results, with binding
energy of -8.20 kcal/mol for human CA I and -8.24 kcal/mol for human CA II. Conclusion: Molecule 4
inhibited only CA I. Its usage as a potential chemotherapeutic agent specific to the CA I isozyme may be
considered.